MRK vs. LLY, JNJ, ABBV, PFE, BMY, ZTS, RPRX, JAZZ, CORT, and PRGO
Should you be buying Merck & Co., Inc. stock or one of its competitors? The main competitors of Merck & Co., Inc. include Eli Lilly and Company (LLY), Johnson & Johnson (JNJ), AbbVie (ABBV), Pfizer (PFE), Bristol-Myers Squibb (BMY), Zoetis (ZTS), Royalty Pharma (RPRX), Jazz Pharmaceuticals (JAZZ), Corcept Therapeutics (CORT), and Perrigo (PRGO). These companies are all part of the "pharmaceuticals" industry.
Merck & Co., Inc. (NYSE:MRK) and Eli Lilly and Company (NYSE:LLY) are both large-cap medical companies, but which is the superior investment? We will compare the two businesses based on the strength of their institutional ownership, dividends, media sentiment, community ranking, risk, earnings, profitability, analyst recommendations and valuation.
Merck & Co., Inc. has a net margin of 21.99% compared to Eli Lilly and Company's net margin of 18.86%. Eli Lilly and Company's return on equity of 67.52% beat Merck & Co., Inc.'s return on equity.
Merck & Co., Inc. pays an annual dividend of $3.08 per share and has a dividend yield of 2.8%. Eli Lilly and Company pays an annual dividend of $5.20 per share and has a dividend yield of 0.6%. Merck & Co., Inc. pays out 342.2% of its earnings in the form of a dividend, suggesting it may not have sufficient earnings to cover its dividend payment in the future. Eli Lilly and Company pays out 76.6% of its earnings in the form of a dividend, suggesting it may not have sufficient earnings to cover its dividend payment in the future. Merck & Co., Inc. has raised its dividend for 13 consecutive years. Merck & Co., Inc. is clearly the better dividend stock, given its higher yield and longer track record of dividend growth.
In the previous week, Eli Lilly and Company had 15 more articles in the media than Merck & Co., Inc.. MarketBeat recorded 48 mentions for Eli Lilly and Company and 33 mentions for Merck & Co., Inc.. Merck & Co., Inc.'s average media sentiment score of 0.55 beat Eli Lilly and Company's score of 0.47 indicating that Merck & Co., Inc. is being referred to more favorably in the media.
76.1% of Merck & Co., Inc. shares are owned by institutional investors. Comparatively, 82.5% of Eli Lilly and Company shares are owned by institutional investors. 0.1% of Merck & Co., Inc. shares are owned by insiders. Comparatively, 0.1% of Eli Lilly and Company shares are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company will outperform the market over the long term.
Merck & Co., Inc. currently has a consensus target price of $133.00, suggesting a potential upside of 21.25%. Eli Lilly and Company has a consensus target price of $979.29, suggesting a potential upside of 5.17%. Given Merck & Co., Inc.'s stronger consensus rating and higher possible upside, research analysts clearly believe Merck & Co., Inc. is more favorable than Eli Lilly and Company.
Eli Lilly and Company received 223 more outperform votes than Merck & Co., Inc. when rated by MarketBeat users. Likewise, 70.57% of users gave Eli Lilly and Company an outperform vote while only 67.19% of users gave Merck & Co., Inc. an outperform vote.
Merck & Co., Inc. has a beta of 0.39, indicating that its stock price is 61% less volatile than the S&P 500. Comparatively, Eli Lilly and Company has a beta of 0.42, indicating that its stock price is 58% less volatile than the S&P 500.
Eli Lilly and Company has lower revenue, but higher earnings than Merck & Co., Inc.. Merck & Co., Inc. is trading at a lower price-to-earnings ratio than Eli Lilly and Company, indicating that it is currently the more affordable of the two stocks.
Summary
Eli Lilly and Company beats Merck & Co., Inc. on 13 of the 22 factors compared between the two stocks.
Get Merck & Co., Inc. News Delivered to You Automatically
Sign up to receive the latest news and ratings for MRK and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding MRK and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NYSE and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Merck & Co., Inc. Competitors List
Related Companies and Tools
This page (NYSE:MRK) was last updated on 10/15/2024 by MarketBeat.com Staff
